Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

This is a prospective, Bayesian adaptive, phase II clinical trial designed to evaluate the safety and efficacy of four treatment regimens in patients with recurrent (unamenable to local therapy) or metastatic nasopharyngeal carcinoma (NPC) who have failed after at least one prior platinum-containing standard regimen and anti-PD-1/PD-L1 therapy. The four treatment arms include: 1. Ivonescimab monotherapy, 2. Ivonescimab combined with nimotuzumab, 3. Liposomal mitoxantrone plus anti-PD-1 antibody, and 4. Liposomal irinotecan plus S-1.

NCT Number	NCT07070479
Lead Sponsor	Ming-Yuan Chen
Conditions	Recurrent or Metastatic Nasopharyngeal Carcinoma
Enrollment	208 participants
Start Date	2025-06-24
Primary Completion	2027-01-30 (estimated)
Study Completion	2028-01-30 (estimated)
Updated on ClinicalTrials.gov	2025-09-18